Drug lookup | Fillwise

PHENYTOIN (DIPHENYLHYDANTOIN)

All products: general benefit

Other products in the same Health Canada class (N03A, N03AB) — coverage varies; not interchangeable

Phenytoin diphenylhydantoin (Dilantin): general benefit, Limited Use 481, 657
Carbamazepine (Tegretol): general benefit, Limited Use, Not a benefit, Listing status unconfirmed
Clonazepam (Rivotril): general benefit
Divalproex (Epival): general benefit
Ethosuximide (Zarontin): general benefit
Lamotrigine (Lamictal): general benefit

14 more in the class list below

Dilantin Infatabs · DIN 00023698 · 50mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Dilantin Infatabs · DIN 00023698 Manufacturer: Upjohn Canada ULC; listing date 1996-10-01 Health Canada: Marketed since 2023-08-02 · brand DILANTIN INFATABS · ATC N03AB02 PHENYTOIN · form Tablet (chewable) · route Oral · ingredients PHENYTOIN 50 MG · company Bgp pharma ulc · schedule Prescription

Check this DIN again · Health Canada product record

Dilantin Infatabs: Formulary list price $0.1092/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1092 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1086 · Verify on the e-Formulary ↗ (DIN 00023698)

Source record

DIN 00023698: Dilantin Infatabs Raw flags: sec3=Y Item: 281200001; group id 439; item number 1099; lccId None; manufacturer id UJC Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.1092; ministry $0.1092 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00023698 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1086

Shortage status: resolved shortage (ended 2026-06-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00023698

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L

VALPROIC ACID

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 250mg, 500mg · Cap, Ent Cap

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab

CENOBAMATE

· 9 products · Limited Use, codes 719 · strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg, 12.5mg & 25mg, 50mg & 100mg, 150mg & 200mg · Tab, Tab - (Starter Kit) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more

Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS DILANTIN INFATABS (phenytoin chewable tablets), DILANTIN-30 SUSPENSION and DILANTIN- 125 SUSPENSION (phenytoin oral suspensions) are indicated for: • the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures. Phenytoin is not effective for absence (petit mal) seizures, and not indicated for seizures due to hypoglycemic or other metabolic causes. 1.1 Pediatrics Pediatrics (< 18 years of age): See 4.2 Recommended Dose and Dosage Adjustments, Pediatrics. 1.2 Geriatrics Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 4.2 Recommended Dose and Dosage Adjustments, Geriatrics. https://pdf.hres.ca/dpd_pm/00071910.PDF PM date: August 2, 2023 Source product: DILANTIN INFATABS; DIN 00023698; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.